# Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction

> **NCT03658031** · PHASE3 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 576 (estimated)

## Conditions studied

- PreDiabetes
- Myocardial Infarction
- T2DM (Type 2 Diabetes Mellitus)
- CVD

## Interventions

- **DRUG:** Dapagliflozin 10mg

## Key facts

- **NCT ID:** NCT03658031
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-01-31
- **Target enrollment:** 576 (ESTIMATED)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03658031

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03658031, "Effect of Dapagliflozin on the Progression From Prediabetes to T2DM in Subjects With Myocardial Infarction". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03658031. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*